Trials / Terminated
TerminatedNCT03532542
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Sarepta Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 7 Years – 23 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Casimersen | Casimersen solution for IV infusion |
| DRUG | Golodirsen | Golodirsen solution for IV infusion |
Timeline
- Start date
- 2018-08-02
- Primary completion
- 2023-07-26
- Completion
- 2023-07-26
- First posted
- 2018-05-22
- Last updated
- 2024-09-19
- Results posted
- 2024-09-19
Locations
50 sites across 13 countries: United States, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Poland, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03532542. Inclusion in this directory is not an endorsement.